Olmesartan Attenuates Cardiac Hypertrophy and Improves Cardiac Diastolic Function in Spontaneously Hypertensive Rats Through Inhibition of Calcineurin Pathway.

Mingqiang Fu,Jingmin Zhou,Jianfeng Xu,Hongmin Zhu,Jianquan Liao,Xiaotong Cui,Aijun Sun,Michael Fu,Yunzeng Zou,Kai Hu,Junbo Ge

DOI: https://doi.org/10.1097/fjc.0000000000000038

IF: 3.271

2014-01-01

Journal of Cardiovascular Pharmacology

Abstract:Objective:To test whether olmesartan ameliorates cardiac diastolic dysfunction in spontaneously hypertensive rats (SHRs) through calcineurin pathway.Methods:Twenty-four male SHRs of 6 months were divided into saline- (n = 12) and olmesartan-treated (n = 12) groups. Age-matched WKY (n = 12) rats served as controls. Saline (10 mL center dot kg center dot d) or the same volume of olmesartan liquor (2.5 mg center dot kg center dot d) was administered by gavage for 3 months. Heart rate, systolic blood pressure, cardiac structure, and function and histological studies were determined. Expression of calcineurin and downstream NFAT3 were also detected.Results:Compared with age-matched Wistar Kyoto rats, SHRs of 6 months exhibited evident cardiac hypertrophy and diastolic dysfunction as demonstrated by elevated systolic blood pressure and E/E ', decreased E/A and E '/A ', while F, left ventricular ejection fraction and fractional shortening remained unimpaired. Treatment with olmesartan significantly decreased systolic blood pressure and ventricular hypertrophy, attenuated fibrosis, and improved diastolic function (all P < 0.05). Meanwhile, both calcineurin and NFAT3 expressions were downregulated in olmesartan group compared with the other 2 groups (both P < 0.05).Conclusions:These data suggest the beneficial effect of olmesartan on cardiac structure and diastolic dysfunction, and it may be mediated through calcineurin pathway. This indicates a new therapeutic target for diastolic dysfunction.